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Abstract Multimedia technologies offer powerful tools to
increase capacity of health workers to deliver standardized,
effective, and engaging antiretroviral medication adherence
counseling. Masivukeni—is an innovative multimedia-
based, computer-driven, lay counselor-delivered interven-
tion designed to help people living with HIV in resource-
limited settings achieve optimal adherence. This pilot study
examined medication adherence and key psychosocial
outcomes among 55 non-adherent South African HIV?
patients, on antiretroviral therapy (ART) for at least
6 months, who were randomized to receive either Mas-
ivukeni or standard of care (SOC) counseling for ART non-
adherence. At baseline, there were no significant differ-
ences between the SOC and Masivukeni groups on any
outcome variables. At post-intervention (approximately
5–6 weeks after baseline), -clinic-based pill count adher-
ence data available for 20 participants (10 per intervention
arm) showed a 10 % improvement for—participants and a
decrease of 8 % for SOC participants. Masivukeni partici-
pants reported significantly more positive attitudes towards
disclosure and medication social support, less social rejec-
tion, and better clinic–patient relationships than did SOC
participants. Masivukeni shows promise to promote optimal
adherence and provides preliminary evidence that multi-
media, computer-based technology can help lay counselors
offer better adherence counseling than standard approaches.
Keywords HIV  ART adherence  Technology 
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Introduction
With documented individual [1–3] and public health [4, 5]
benefits of early antiretroviral therapy (ART), increasing
numbers of people living with HIV worldwide are initiat-
ing treatment. However, optimal medication adherence is
needed to achieve and sustain the viral suppression nec-
essary for a person living with HIV to remain healthy and
reduce the likelihood of transmitting the virus to others [6–
8]. Unfortunately, achieving and sustaining high levels of
medication adherence is a challenge for many individuals
and requires ongoing attention as well as retention in care
[9]. Over-burdened healthcare systems often must rely on
minimally trained, non-clinical personnel (e.g., lay coun-
selors) to implement behavioral interventions for adher-
ence and provide ongoing support to patients living with
HIV, some of which may be beyond the limits of their
current competencies. This is especially true in high
prevalence and resource-constrained settings such as Sub-
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Saharan Africa where some health service responsibilities
have been shifted from physicians and nurses to less spe-
cialized personnel [10, 11] in the context of expanding
ART programs [12–15].
In the Western Cape of South Africa, ART adherence
counseling is performed by lay counselors who are usually
trained and certified by non-governmental organizations
(NGOs) that work with the national and local departments
of health. These counselors typically receive about
1 month of adherence counseling training and, once certi-
fied, are placed in clinics to identify and address patients’
adherence problems. However, support and supervision is
often minimal and sporadic, and counseling can vary
widely. In the face of this challenge, the use of technology
has the potential to standardize and improve the quality of
adherence intervention delivery.
Technology-based, multimedia interventions increas-
ingly are being implemented to promote engagement,
learning, standardization, and delivery of health interven-
tions [16], and they have led to health improvements in
asthma [17, 18], diabetes [19], smoking [20, 21], and
alcohol use [22, 23] in the US. Compared to non-technol-
ogy-based interventions, multimedia-based programs have
demonstrated better short- and long-term efficacy for
health behavior change and good feasibility across a range
of populations [24–27]. Further, they are liked by users and
appear to be more time efficient and cost-effective than
traditional approaches [28, 29]. Numerous computer-based
HIV prevention interventions have been developed and
have been shown to improve condom use [30]. One mul-
timedia, patient-administered, computer-based intervention
for ART adherence, ‘‘Life Windows,’’ has been developed
and tested in the US, which showed promise for software
based programs to improve adherence behavior [31].
To address the antiretroviral adherence counseling needs
of South Africa and the millions of HIV-infected individ-
uals who are on or will be initiating ART, as well as the
healthcare personnel shortage in that country, we devel-
oped a computer-based, multimedia adherence intervention
for lay adherence counselor administration to patients on
ART in South African health clinics. The computer-based
component of the intervention serves as an interactive
guide for the lay counselors to stay on track and ensure all
the curriculum is delivered, and as an interactive tool to
engage patients in their care, as well as in understanding
HIV and ART. Working closely with South African and
new media colleagues, we developed a 6-session, com-
puter-based, multimedia adherence intervention designed
to improve the quality and enhance the capacity of lay
counselors to deliver Department of Health required ART
adherence counseling. The intervention was adapted from
the Sharing Medical Adherence Responsibilities Together
(SMART) Couples intervention [32, 33], as well as from
activities developed in Multimedia Connect [34]. The
intervention was named ‘‘Masivukeni’’ (‘‘Let’s Wake Up’’)
by its South African healthcare providers and patients
involved in its development and design.
Masivukeni is designed to be used by lay adherence
counselors during the counseling sessions with patients as
both a guide to the intervention curriculum (helping
counselors know what content has and has not been cov-
ered with each patient), and a multimedia tool to convey
complex information to patients in novel, easy-to-under-
stand formats (for an overview of the intervention design
see: https://www.youtube.com/watch?v=MOGlicrnko0).
Elsewhere, we have extensively described the process of
adaptation and development of the intervention for the
South African context and reported its high acceptability
by patients, counselors, and clinic administrators, as well as
the feasibility of its use in a busy resource-constrained
healthcare setting [35]. Table 1 shows the curriculum,
objectives, and activities for each session of Masivukeni.
Masivukeni’s multimedia foundation was programmed in
HTML and is presented in a webpage format, but an internet
connection is not required to administer the intervention.
Only minimal computer literacy is required to operate the
program (i.e., knowledge of how to use a mouse and key-
board, open and close programs, and use a username and
password). The user interface was designed to be simple and
provide a roadmap for each session—through simple
graphics, counselors can see quickly where they are in each
session and which activities they have completed and have
yet to complete. Counselors and patients can enter responses
to questions and manipulate virtual objects in order to apply
new concepts, explore hypothetical scenarios, practice new
skills, test knowledge, and set goals for future sessions. Short
videos are used to convey complex and difficult HIV infor-
mation (e.g., drug resistance, ART adherence, and problem-
solving approaches to address adherence barriers) and are
easily viewed, paused, and reviewed at the patients’ and/or
counselor’s discretion. Masivukeni also was programmed
with embedded standardized mental health and substance
use screening questions that provide standardized referral
scripts for patients who have scores indicating the possible
presence of such problems.
Activity completion information, as well as patient ini-
tiated and/or counselor initiated questions, are saved from
session to session so that patients and counselors can
review questions that were asked in previous sessions, and
see which activities were completed previously and which
ones still need to be done. The program records and tracks
all data entered by the facilitator or patients, records the
time that was spent on each activity, and can print a packet
of information tailored to a particular patient’s sessions.
We have previously reported that lay counselors using
Masivukeni indicated that it helped them engage patients
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Table 1 Masivukeni sessions overview
Session Participant(s) Objectives
1 Patient Develop rapport and understanding of intervention goals
Screen for mental health and substance use problems and make necessary referrals
Assess other psychosocial needs related to HIV care and prevention
Increase commitment to medical (including medication) adherence
Review patient’s social support network and identify a treatment support partner
Identify personal reasons for staying healthy
Multimedia activities
Mental health and substance use screening questions automatically score results and provide counselors with
severity appropriate scripts for referrals
Interactive: Support Tree Activity (visually and dynamically represents support network and who in the
network knows patient’s HIV status and/or who can offer practical support)
Interactive: Reasons to stay healthy (visually depicts patient’s top several reasons to stay healthy)
2 Patient and support
partner
Develop rapport and understanding of intervention goals with partner
Increase knowledge of HIV, ART, resistance, and need for high levels of adherence
Review reasons for staying healthy; make changes if wanted
Multimedia activities
Interactive: Island Activity 1 (visually and dynamically depicts the relationship between CD4 count and viral
load
Interactive: Island Activity 2 (visually and dynamically depicts the relationship between ART adherence, CD4
count and viral load)
Interactive: Pill Regimen Activity (visually and dynamically represents number of pills in patient ART
regimen and dosing times)
Video: Dramatically illustrate viral resistance and the importance of adherence using snakes to represent HIV
and soldiers to represent the immune system
Interactive: Reasons to stay healthy (visually depicts patient’s top several reasons to stay healthy)
3 Patient and support
partner
Reinforce importance of adherence and good health care
Promote adherence self-efficacy
Teach problem-solving skills and how to apply them to adherence barriers
Review reasons for staying healthy; make changes if wanted
Multimedia activities
Video: Demonstration of problem-solving for ART adherence with South African actors
Interactive: Problem-solving Activity (choose barriers from menu and complete action plan)
4 Patient and support
partner
Practice problem-solving
Review modes of HIV transmission and importance of HIV transmission prevention
Review reasons for staying healthy; make changes if wanted
Multimedia activities
Game: HIV ‘‘Myth/Fact’’ (patient and partner are given statements about HIV transmission and asked to
determine if they are true or false
5 Patient and support
partner
Practice problem-solving
Discuss the importance of thoughtful disclosure and how it can benefit adherence
Multimedia activities
Video: Dramatic portrayals of Hope and Joseph where Hope enlists the help of her brother to help her stay
adherent and Joseph hides his HIV status and medications from his family. Hope stays healthy and Joseph
falls very ill
6 Patient and support
partner
Build support and confidence to access and communicate with members of the healthcare team
Review the Support Tree and make any changes/additions
Review other activities as per counselor discretion and/or patient request
End program with patient and support partner committing to help each other stay healthy
Multimedia activities
Use of any previous activity or video as needed
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better than the standard counseling methods and proce-
dures; stay on track with the intervention content, curric-
ulum and health messages; and remember to cover
important information and material [35]. In this report, we
present a first analysis of the impact of Masivukeni on ART
adherence outcomes and the behavior change mediators
hypothesized within our theoretical framework, Social
Action Theory [36], in a pilot sample of HIV-infected
patients taking antiretroviral medication (ARVs) at one
public health clinic in South Africa.
Method
Participants and Procedures
The study was conducted between August, 2008, and April,
2010, at a City of Cape Town Department of Health primary
health clinic that provides HIV care and ART and is located
near a large township. Eligible patients were HIV?, 18 years
or older, on ART for at least 6 months, identified as non-
adherent (\90 % adherence by clinic-based pill count,
detectable viral load, or other clinical signs of non-adher-
ence, such as the presence of opportunistic infections and
other HIV-related medical comorbidities as identified by the
patient’s provider and/or medical record), and willing to
bring a treatment support partner (‘‘buddy’’) to counseling
sessions. The clinic policy at that time followed the City of
Cape Town Department of Health (DOH) requirements
requiring all patients receiving ART adherence counseling to
bring a treatment support partner to counseling sessions. This
often meant that patients would ask another available patient
they met in the waiting room to attend their session with them
[35]. In practice, counselors were able to counsel some
patients if they did not bring a buddy. Clinic staff offered
participation in this study to potentially eligible patients
who, having been non-adherent, were being asked to come
back to the clinic for additional ART counseling sessions.
Interested patients then met with the study coordinator who
described the study and conducted eligibility screening.
Sixty-five participants were recruited and enrolled in the
study. After the study coordinator obtained informed con-
sent, the participant completed a baseline assessment
(approximately 90 min; see Measures) administered by
study staff, and was then randomized to receive either
Masivukeni or SOC counseling. The study statistician gen-
erated a randomization list that was provided to the South
African Project Director (PD) to use to assign participants to
the appropriate study arm. The PD remained blind to the next
assignment until after eligibility, consent, and baseline
assessment were completed.
Patients in the Masivukeni condition completed the first
session of their 6-session non-adherence counseling
immediately or were scheduled to return to the clinic to
complete within 2 weeks. Sessions were then scheduled
approximately 1 week apart. If a patient randomized to
Masivukeni did not return for a scheduled session, the
study counselor called and/or texted him/her to reschedule
the session. At the time of the study, no standardized
counseling curriculum existed for counseling patients who
were having problems with medication adherence, thus
leaving the SOC counselors to address adherence issues in
whatever manner they decided was needed for the patient.
All participants completed a post-intervention assess-
ment; those in the Masivukeni group completed it imme-
diately after their final counseling session, which ranged
from 5 to 6 weeks after their baseline assessment. To
establish equivalent timing (relative to baseline assess-
ment) of the post-intervention assessment between groups,
those in the SOC group completed it approximately
5–6 weeks after their first SOC counseling session (cal-
culated from the day of study enrollment).
Participants in both arms received compensation for
transportation (approximately $5 equivalent) to and from
each counseling session, and compensation (another
approximately $5 equivalent) for completing the assess-
ment. All procedures received approval from the Human
Research Ethics Committee of the University of Cape
Town and the Institutional Review Board of the New York
State Psychiatric Institute.
Masivukeni Intervention
To administer the Masivukeni intervention, we hired two
lay counselors who had received adherence counseling and
HIV testing and counseling training from the local NGO (see
standard of care below) and had previous experience work-
ing in clinics conducting HIV testing and counseling, as well
as ART adherence counseling. They were trained in the use
of Masivukeni (i.e., how to operate the program and navigate
through the intervention) and how to integrate their current
adherence counseling skills and knowledge with Masivuk-
eni. We have described in detail the content of the six-session
Masivukeni intervention previously [35], and Table 1 pro-
vides an overview of the content and curriculum. In the first
Masivukeni session, the counselor was guided by the com-
puterized program (see Figs. 1 and 2) in administering
standardized screening assessments for psychiatric distress
and problems with alcohol and substance use. Scores were
automatically and immediately provided, along with scrip-
ted messages to give to the patient tailored to level of
impairment, if any. The session was also focused on selecting
an optimal support partner by using the interactive Support
Tree Activity Fig. 3. The participant then invited the treat-
ment support partner to attend the remaining five Masivukeni
sessions in which the counselor used the laptop computer to
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guide the counseling; engage the patient and support partner
with short videos and multimedia, interactive activities to
illustrate and explain complex HIV medical information and
behavioral components of adherence; and identify and
problem-solve adherence barriers specific to the patient
(Figs. 4–6). The support partner was encouraged to come
back to the remaining sessions.
Standard of Care
SOC counselors were the existing staff counselors at the
clinic site (who had also received the same adherence
counseling, as well as HIV testing and counseling training
through the local NGO). Because there was no standard
counseling curriculum for patients with adherence prob-
lems, participants randomized to SOC non-adherence
counseling met with the SOC counselors as often and for as
long as the counselor deemed necessary, which in practice
often amounted to a single, brief (\15 min) session. The
SOC counseling curriculum consisted of information about
HIV disease, ARVs, the importance of adherence, resis-
tance, and healthy living and was typically presented via a
flipchart. While it is the policy of the DOH to have a
treatment buddy attend adherence counseling sessions with
the index patient, in actual practice, many SOC counselors
allowed counseling to occur without a treatment partner
being present or allowing the patient to bring in a ‘‘partner’’
whom the patient was able to recruit from the waiting room
(not necessarily a person in their social network).
Measures
The assessment battery was developed by a combined US-
South Africa team of investigators in accordance with
Social Action Theory (SAT; see Fig. 7) [36, 37], which
posits that behavioral health outcomes are mediated by
contextual factors (e.g., demographics, health care systems,
and mental health) and by self- and social-regulation fac-
tors (e.g., self-efficacy, health beliefs, social relationships,
and stigma). All measures were translated from English
into Xhosa and back-translated by linguistic experts at the
University of Cape Town. They were also reviewed by
Xhosa-speaking study staff to ensure accurate and mean-
ingful translations. All assessments were administered by
trained research assistants.
Contextual Influences
Demographic and medical information was obtained by
participant self-report. Participants were asked when they
were diagnosed with HIV, how long they had been on
ARVs, their most recent CD4 count (if known), and stan-
dard demographic questions (e.g., age, education, etc.).
Clinic–patient relationship was assessed with 12 items
via a 4-point scale (‘‘Never’’ to ‘‘Every time’’) adapted
from the Physician–Patient Relationship Quality Scale [38]
in which participants were asked to rate how they felt about
their experience receiving care from the clinic (for exam-
ple, How often do you ‘‘Feel that the clinic staff really
listens to your concerns?’’ and ‘‘Get asked by the clinic
staff about how well you are able to take your medications
as prescribed.’’). Items were summed to create a total score
in which higher scores reflected more positive clinic–
patient relationships. Cronbach’s a = 0.90 for this sample.
Mental healthwas assessed with the Kessler 10 (K10) [39,
40], which assesses general mental health functioning via 10
items with a 5-point Likert-type scale (‘‘None of the time’’ to
‘‘All of the time’’). Sample items include, ‘‘During the past
month, that is from [date one month ago] to yesterday, about
how often did you feel:…,’’ ‘‘Tired out for no good reason,’’
and, ‘‘Worthless.’’ Items were summed to create a total K10
score in which higher scores indicated more psychiatric
distress. Cronbach’s a = 0.84 for this sample.
Self-Regulation
Adherence self-efficacy was assessed via 14 items from the
AACTG adherence instruments [41]. Participants were asked
to rate how confident they would be in taking their medica-
tions in different circumstances (e.g., when busy, feeling
healthy, drinking alcohol, etc.) on a 5-point likert-type scale
ranging from ‘‘Not at all confident’’ to ‘‘Completely confi-
dent.’’ Items were summed to create a total adherence
self-efficacy score in which higher scores indicated more self-
efficacy. Cronbach’s a = 0.84 for this sample.
Attitudes towards disclosure was assessed via five items
that asked participants how much they agreed or disagreed
(on a 4-point Likert-type scale where 1 = Strongly dis-
agree and 4 = strongly agree) with statements such as ‘‘In
general, disclosing my HIV status to other people in my
Fig. 1 Adapted social action theory constructs and accompanying
measures (italics)
AIDS Behav (2015) 19:S163–S176 S167
123
Fig. 2 Intervention home page.
The Homepage lists all the
sessions. When counselors click
on a Session box, they are taken
to the Session page (see Fig. 3).
When all the activities in a
session are complete, the
session box turns green. This
helps counselors know where
they are in the intervention and
which sessions have been
completed (Color figure online)
Fig. 3 Session page user
interface. The Session page
displays the goals of the session
as well as the list of activities.
Counselors and patients are able
to see how many activities are
in the session, and which ones
have been completed (Activity
box turns green when
complete). This helps
counselors know where they are
in the intervention and which
sessions have been completed
(Color figure online)
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community can be helpful to me,’’ and, ‘‘I find it easy to
disclose my HIV status to other people.’’ Items were
summed to create a total score (with two items being
reverse-scored) in which higher scores indicated more
favorable attitudes towards disclosing one’s HIV status.
Cronbach’s a = 0.62 for this sample.
Fig. 4 Support Tree Activity.
Orange colored tree fruits
indicate disclosure status
(orange = disclosed to). The
purple ring around the fruit
indicates that the person is a
source of practical support
(Color figure online)
Fig. 5 HIV Knowledge (Island)
Activity. Patients and partners
can move the sliders up and
down. As viral load goes up and
cd4 count goes down, the person
on the island becomes thinner
and the water level rises
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Beliefs about medications was assessed by the 5-item
Necessity Subscale from the Beliefs about Medication
Scale [42] that assesses individual views about HIV med-
ications (Part A) and personal views on medications in
general (Part B). Higher scores on the Necessity Subscale
indicate stronger beliefs that ARVs are important and the
benefits of ARVs outweigh their challenges. Cronbach’s
a = 0.60 for this sample.
HIV/AIDS knowledge was assessed via the 11-item HIV/
AIDS Knowledge Inventory [43]. Participants were asked
specific questions about what causes HIV and how it is
transmitted (e.g., ‘‘Is HIV the virus that causes AIDS?’’ and
‘‘Is HIV/AIDS spread by kissing?’’) and given the response
options of ‘‘Yes,’’ ‘‘No,’’ and ‘‘Don’t know.’’ A total score
was computed, such that higher scores indicated more
correct knowledge of the disease and how it is transmitted.
Cronbach’s a = 0.69 for this sample.
HIV Treatment Knowledge was assessed by the 12-item
HIV/AIDS Treatment Knowledge Inventory [44, 45]. Par-
ticipants were asked to respond ‘‘True,’’ ‘‘False,’’ or
‘‘Don’t Know’’ to statements about ART and other aspects
of HIV treatment, such as ‘‘CD4 counts are used to mea-
sure immune system functioning,’’ and ‘‘Taking antiretro-
viral therapy exactly as prescribed is likely to reduce viral
load.’’ A total score was computed such that higher scores
indicated more correct knowledge about HIV/AIDS treat-
ment. Cronbach’s a = 0.67 for this sample.
Social-Regulation
Medication-specific social support was assessed via 8
items, each with a 5-point Likert-type scale (‘‘Never’’ to
‘‘Very often’’) [46]. Individuals were asked, ‘‘How often
has someone in the past three months……’’ ‘‘Helped you
monitor your symptoms and medication side effects?’’ and
‘‘Checked in with you about your medications?’’ Items
were summed (and reverse-coded when necessary) to
Fig. 6 HIV Knowledge (Island)
Activity 2. Patients and partners
can move the adherence slider
up and down. As adherence
goes up, viral load goes down,
cd4 count goes up, and the
person on the island becomes
moves up the mountainside
Fig. 7 Pill Regimen Activity. Patients and partners can move their
regimen pills into the cups. If they make mistakes, the counselor will
correct them
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create a total score in which higher scores indicated more
support. Cronbach’s a = 0.88 for this sample.
Perceived availability of social support was assessed via
an 8-item scale [47, 48] asking on a 5-point Likert-type
scale (‘‘Definitely No’’ to ‘‘Definitely Yes’’) how likely the
respondent would be able to get different types of support.
Example items are, ‘‘Is there someone you could contact if
you wanted to talk about an important personal problem
you were having?’’ and ‘‘Is there someone you could turn
to if you needed to borrow $10, get a ride to the doctor, or
some other small immediate help?’’ Items were summed
(and reverse-coded when necessary) to create a total score
in which higher scores indicated more perceived social
support. Cronbach’s a = 0.82 for this sample.
HIV-related stigma was assessed via the 9-item Social
Rejection subscale of the Social Impact Scale [49]. Indi-
viduals were asked to agree or disagree (on a 5-point
Likert-type scale) with statements about their experiences
of other people since becoming infected with HIV. For
example, items asked, ‘‘I feel that I have been treated with
less respect than usual by others,’’ ‘‘I feel some friends
have rejected me because of my illness,’’ and, ‘‘Due to my
illness, others seem to feel awkward and tense when they
are around me.’’ Items were summed (and reverse-coded
when necessary) to create a total score in which higher
scores indicated more stigma related social rejection.
Cronbach’s a = 0.81 for this sample.
Behavioral Health Outcomes
Objective ART adherence was measured by the standard
clinic-based pill count as established by the clinic phar-
macy and City Department of Health and conducted at each
pharmacy ARV refill. The pharmacist formula for calcu-
lating percent adherence was as follows:
An adherence percentage was calculated for each medi-
cation in the regimen with higher percentage indicating
higher adherence. For this study, we compared the clinic-
based pill count data for the 30-day period prior to enrolling
in the study and the clinic-based pill count data at the refill
period closest to the 1-month follow-up time point.
Self-report ART adherence was assessed with one item
from the AACTG asking participants to rate their adher-
ence over the past 4 weeks ‘‘Thinking about the past
4 weeks, how often did you take all of your HIV
antiretroviral medications as your doctor prescribed
them?’’ [41]. Responses ranged from ‘‘All of the time’’ to
‘‘None of the time.’’ A short preamble to the question
reminded participants that many people struggle taking
their ARVs as prescribed.
Data Analysis
Descriptive statistics were generated overall and by group
for all SAT constructs: self- and social-regulation, con-
textual factors, and behavioral health outcomes at baseline.
This small pilot study was not powered to determine
intervention efficacy but rather to evaluate acceptability
and feasibility of the intervention and to determine whether
there were any changes in the desired direction in the
proposed mediators and behavioral outcomes. Therefore,
for this report, we provide routine point estimates and
confidence intervals to evaluate parameter values that
would not be ruled out by the pilot results. We compared
Masivukeni participants to SOC participants in terms of
their mean change from baseline to post-intervention in
medication adherence measured by clinic-based pill count
and self-reported adherence, self- and social-regulation,
and contextual factors. We used generalized linear models
(GLM) with identity link function to examine the change
over time. The model included the group indicator for
Masivukeni (vs. SOC), the indicator for time (baseline vs.
post-intervention), and the interaction of the two indicators.
The regression coefficient corresponding to the group-by-
time interaction term estimates the difference between the
two study group populations’ mean changes in study out-
comes over time and, thus, represents the effect of the
Masivukeni intervention on change in the outcomes of
interest. We employed generalized estimating equations
(GEE) to account for the effect of intra-cluster correlations




Table 2 presents the overall demographics and self-repor-
ted medical history of enrolled participants. There were no
Number of pills out from previous refillð Þ  Number of pills in at current refillð Þ
Days since last refillð Þ  Number of pills prescribed per dayð Þ
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differences in demographic and medical variables between
intervention groups. All participants were Black, and 94 %
spoke Xhosa at home. Most participants were on the cur-
rently available (at the time of this study) first-line ARV
regimen, which consisted of 3TC (1 pill twice per day),
D4T (1 pill twice per day), and efavirenz (1 pill once per
day) or neviropine (2 pills twice per day), for a total pill
burden of 5–6 pills per day with two dosing times per day.
Fixed dose combinations were not available to any patients
during the course of this study. Eleven participants were
prescribed second line regimens, most consisting of DDI
(either 50 mg or 100 mg, twice per day) and Kaletra or
Aluvia (4 pills, twice per day). There were no differences
in regimens between groups.
Sixty-five participants were enrolled at baseline, 33
were randomized to receive Masivukeni and 32 to SOC.
Eighty-five percent (n = 55) were retained at post-inter-
vention. Of the 33 participants randomized to Masivukeni
27 (82 %) completed all six sessions and the post-inter-
vention assessment. Of the 32 participants randomized to
SOC, 28 (88 %) completed the post-intervention assess-
ment. The most common reasons for study ‘‘drop-out’’
were moving out of the area, illness or hospitalization,
conflict of clinic attendance with employment, and clinic
loss to follow-up; most participants who did not complete a
post-intervention assessment also did not return to the
clinic for medication refills during that period. There were
no differences between intervention arms on reasons for
drop-out. In sum, we were able to complete the pilot study
with 86 % of participants who initially enrolled and 96 %
of participants who came to the first Masivukeni session.
SAT Model Constructs
Table 3 presents means for SAT model constructs grouped
by domain. At baseline, there were no significant differ-
ences between the SOC and Masivukeni groups on any of
the psychosocial or adherence measures. The point esti-
mates of the Masivukeni intervention effect at post-inter-
vention for all outcomes of interest are presented together
with their 95 % confidence intervals and corresponding
p values.
Self-Regulation
Adherence self-efficacy and attitudes towards disclosure
increased in both groups between baseline and post-inter-
vention. Only the increase in attitudes towards disclosure
was statistically significantly different between the study
arms, with participants in Masivukeni reporting signifi-
cantly more positive attitudes towards disclosure at post-
intervention than participants in the SOC group. Positive
beliefs about medication increased in the Masivukeni
group and decreased in the SOC group. Though not sta-
tistically significant, the difference in change between the
two groups was at a trend level (p = 0.15), and suggests
that Masivukeni participants may have had more positive
beliefs about ART than those in the SOC group after the
intervention. HIV/AIDS knowledge also increased slightly
in both groups, though there was no statistically significant
difference between groups in this change. HIV treatment
knowledge increased slightly in the Masivukeni group and
decreased slightly in the SOC group, though these changes
were not significantly different.
Social-Regulation
Among our measures of social-regulation, medication spe-
cific social support increased in both groups between base-
line and post-intervention, with the increase in the
Masivukeni group being statistically significantly greater
than that in the SOC group, and those in the Masivuekni
group reporting significantly more medication specific social
support to take their ARVs at post-intervention assessment.
Table 2 Participant
characteristics
There were no significant
differences between groups
Control (N = 32) Intervention (N = 33)
Mean or
percent
SD or N Mean or
percent
SD or N
Age (in years) 38.46 9.11 38.46 9.11
Percent female 66 % 21 67 % 22
Percent completed high school 3 % 1 0 % 0
Percent currently employed 9 % 3 9 % 3
Percent currently in a relationship 53 % 17 30 % 10
Percent no food at least once in past month 47 % 15 28 % 16
Years since HIV diagnosis 5.59 3.54 5.59 3.54
Years on antiretroviral therapy 3.34 2.74 3.34 2.74
Self-reported most recent CD4 count 259 138 259 138
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Perceived availability of social support also slightly
increased in both groups, but the difference in these changes
between groups was not statistically significant. On our
measure of HIV related stigma, participants in the Mas-
ivukeni group showed significantly greater decreases in
social rejection at post-intervention than did participants in
the SOC group. At post-intervention, those in the Masivuk-
eni group reported greater decreases in HIV-related social
rejection than did those in the SOC group.
Contextual Influences
Among our measures of contextual influences, scores on
clinic–patient relationship did not increase in the SOC
group between baseline and post-intervention, but increased
by almost five points in the Masivukeni group. This dif-
ference in the changes between groups approached statis-
tical significance (p = 0.05) and suggests that the
Masivukeni patients developed a better, more positive
relationship with the clinic than did participants in the SOC
group. Scores on the mental health scale decreased in both
groups between baseline and post-intervention, though the
difference in the changes between groups was not statisti-
cally significant.
Behavioral Health Outcomes
Due to incomplete and/or missing pill count records in the
clinic, we were only able to include a subsample of 20 (10
per group) in the analysis of objective adherence based on
clinic-based pill count records. The analysis suggested that
Masivukeni participants’ adherence improved by 10 %,
while SOC participants’ adherence declined by 8 %, and
the difference in these changes between groups was at the
trend level of difference (p = 0.17). The proportion of
participants who achieved 80 % adherence or greater at
post-intervention, based on the clinic-based pill counts,
was 67 % among Masivukeni participants and 16 % among
SOC participants (p\ 0.05). Self-reported adherence
increased slightly in both groups, but the difference in the
changes between groups was not statistically significant,
and, at both time points, mean scores approached the
ceiling of the measure with most participants reporting
very high adherence at baseline and post-intervention.
Discussion
In this pilot study, we set out to make preliminary com-
parisons of a multimedia-based, lay counselor-delivered
Table 3 Baseline and post-intervention results between groups
Variable Baseline Post-intervention Betaa 95 % CI pa
Control Intervention Control Intervention
Higher scores = better,
except where noted
(n = 32) (n = 33) (n = 28) (n = 27)
Mean SD Mean SD Mean SD Mean SD
Self-regulation
Adherence self-efficacy 59.72 (9.14) 60.14 (9.45) 64.44 (5.96) 63.79 (7.17) -1.07 (-6.56, 4.41) 0.70
Attitudes towards disclosure 10.07 (2.03) 9.71 (2.38) 10.81 (1.81) 11.83 (1.78) 1.38 (0.07, 1.68) 0.04
Beliefs about medications 7.45 (3.48) 7.64 (4.11) 7.19 (2.66) 8.96 (3.00) 1.59 (-0.59, 3.77) 0.15
HIV/AIDS knowledge 8.54 (0.58) 8.58 (1.14) 8.88 (0.54) 8.76 (0.97) -0.15 (-0.71, 0.40) 0.59
Treatment knowledge 10.69 (0.81) 9.94 (2.18) 10.61 (1.23) 10.45 (1.14) 0.60 (-0.38, 1.58) 0.23
Social-regulation
Medication social support 22.55 (7.88) 21.50 (8.53) 24.30 (7.18) 28.00 (7.25) 4.75 (0.77, 8.74) 0.02
Perceived availability of social support 30.28 (6.53) 28.94 (7.25) 31.82 (4.46) 32.68 (6.69) 2.20 (-1.27, 5.66) 0.21
Stigma/Social Rejection
Scale (higher = worse)
18.42 (4.20) 18.69 (4.80) 19.58 (4.61) 16.92 (3.88) -2.93 (-5.29, -0.56) 0.02
Contextual influences
Clinic–patient relationship 35.41 (7.05) 36.00 (9.36) 35.48 (6.33) 40.38 (5.14) 4.31 (0.05, 8.57) 0.05




66.26 (24.53) 63.70 (21.69) 58.39 (22.60) 74.21 (25.13) 0.18 (-0.08, 0.45) 0.17
Self-reported adherence 4.28 (1.22) 4.29 (1.19) 4.54 (0.99) 4.57 (1.16) -0.01 (-0.80, 0.77) 0.97
a Beta represents the difference of mean change over time (from baseline to 1-month post-intervention) between Masivukeni and SOC, where
p is the p value corresponds to whether the difference in beta is significantly different from 0
b From pill count data, represents 1 month before and after baseline interview, respectively. This is also on a subset of full sample (n = 20)
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adherence intervention with standard of care (SOC) ART
adherence counseling for patients who were experiencing
medication adherence problems. We have previously
described the feasibility of Masivukeni and its high
acceptability among patients, lay counselors, and clinic
administrators [34]. Here, we report that, at post-inter-
vention, those in the Masivukeni arm had increased med-
ication adherence, whereas those in the SOC arm had
decreased adherence. Though these changes in adherence
rates between groups were not statistically different at post-
intervention, they point to an important trend that warrants
further investigation. We also found significant differences
and trend differences in several variables embedded in
SAT, that were hypothesized to be mediators of changes in
adherence behaviors, including contextual influences and
self- and social-regulation (see Table 3). These were fac-
tors that were addressed in Masivukeni, thus providing
preliminary evidence that this intervention shows promise
in addressing important psychosocial factors that can lead
to improved patient outcomes. Since this was a pilot fea-
sibility study, lacking sufficient sample size and thus power
to test efficacy, we cannot generalize from these findings.
Nevertheless, we are optimistic about the potential of
Masivukeni to show a range of significant differences in a
larger randomized controlled trial (currently underway in
South Africa).
While findings from this pilot study suggest that Mas-
ivukeni holds promise as an effective ART adherence
intervention to improve behavioral adherence and impor-
tant psychosocial influences on ART adherence, we also
note several study limitations. First, the pilot study was
conducted at only one clinic site and with a small sample,
thus findings cannot be generalized to the larger patient
population in the region. Second, for the objective adher-
ence outcome measure, our sample size was further
restricted because clinic-based pill count data were not
available on all participants. Furthermore, the pill count
data that was available to use may be inaccurate due to pill
dumping. Hence, we must interpret the findings from the
pill count data with caution. In fact, we have since learned
that the City of Cape Town is exploring other measures of
adherence because of the difficulties that clinic pharmacies
are having conducting consistent and accurate pill counts.
Third, this was the first time many of the measures in this
study were used with this population. Hence, further
research is needed to further validate these measures within
this population. Finally, our study did not assess long-term
effects of Masivukeni, and it is widely known that behav-
ioral interventions often show steep declines in effective-
ness at longer post-intervention follow-up periods [50].
Evaluation of longer-term effects of Masivukeni is the
subject of our larger randomized controlled trial currently
in the field.
Adherence rates in both study arms, even after the inter-
vention, were low and on average far below the optimal 95 %
recommended adherence rate. This is likely because partic-
ipants in the study were among the sickest and most chal-
lenged with adherence. Nevertheless, even a 10 % increase
in adherence, like we observed, with highly potent regimens
has the potential to improve clinical outcomes. Furthermore,
the proportion of participants achieving 80 % adherence or
greater was much higher among Masivukeni than SOC
participants. With the hopeful advent of more potent and
forgiving regimens, 80 % adherence may be able to help
individuals achieve viral suppression.
Technologies, such as Masivukeni, have the potential to
enhance quality assurance of adherence counseling. For
example, in the Western Cape Region, many lay counselors
do not receive consistent and regular supervision due to
limited resources. In Masivukeni, sophisticated computer
programming tracks and records delivery of and time spent
on key intervention components. In addition to docu-
menting which counselors met with which study partici-
pants, the Masivukeni program records which activities
have been completed (or missed) and the time spent on
each task for each patient.
Masivukeni has built-in mental health and substance-use
screening tools that guide the counselor in administering
standard screening assessments and delivering scripts that
are tailored to the patient’s score and level of distress or
impairment. Masivukeni keeps track of high scores on
these screening tools and whether an appropriate referral
was made. These types of process and screening tools,
which are relatively simple to include during initial soft-
ware development, can assist clinic administrators in
ensuring that counselors are spending appropriate amounts
of time with patients and covering all of the intervention
activities. Clinic administrators can then use these data to
correct lapses in patients’ receipt of counseling services
and thus improve service delivery. These technological
tools have the potential for applicability across a wide
range of health conditions and healthcare settings.
It has been documented that interactive video enhances
transfer of learning and has produced health improvements
in the management of chronic illness [51, 52]; and Mas-
ivukeni’s computer-based tool includes enhanced scripted
text, imagery, animations, audio, and video to deliver
critical information and concepts as well as to model
desired behaviors. In our previous work, we found that the
multimedia foundation of Masivukeni enables lay adher-
ence counselors to deliver the intervention in an engaging
and structured way while overcoming challenges associ-
ated with their own limited education, training, and
supervision and their patients’ low literacy levels [35].
Related, multimedia, computer-based interventions such as
Masivukeni can maximize standardization of intervention
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delivery, even by counselors with varying backgrounds,
training, and capacity, thus taking full advantage of the
potential of task-shifting in the health care system. Tech-
nological solutions to ART adherence, such as Masivukeni,
may prove cost-effective, feasible, and acceptable in
resource-constrained settings, such as South Africa, and
more importantly, may enhance the quality of lay coun-
seling, which can help ART patients maintain better
adherence and healthier lives.
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